The funding round will support the clinical development of the company's transdermal testosterone patch for post-menopausal women.
"Having the funding in place for the first clinical trial of our testosterone patch for post-menopausal women will enable Medherant to take a major step towards registration of the product and being able to address this significant gap in the options available for women in this very important stage of their lives."
SFC Capital led the pre-seed round, which will fund team expansion and product development.
"Livestock producers require advanced technology to optimise their business, and in the near future, measuring their carbon footprint will become mandatory. SFC Capital recognised this need and aided in backing Pastoral in their journey to become the leading regenerative farming solution,"
The funding round was led by Archangels to support product development and US commercialisation.
"Bioliberty has developed a highly effective solution for helping patients with hand weakness, with the potential to improve the quality of life for millions worldwide. We believe its technology has far-reaching benefits beyond this first application, providing the business with an excellent opportunity to grow quickly from its base here in Scotland. Archangels is excited to be supporting the team as they finalise what we hope will be the first of many products and start scaling up their sales activity."
The climate tech company added backing from Bayes Entrepreneurship Fund, One Planet Capital and Cell Capital to complete a £4.1m total Series A round.
"Impact is at the core of what we do at AirEx: to help the decarbonisation of homes and eliminate Fuel Poverty. With the help of this investment and business support we are well positioned to execute our vision – to become a ‘no brainer’ solution for social landlords and homeowners looking to reduce energy consumption in a non-disruptive way. We are truly excited to have the support of such like-minded, mission driven investors."
GIC led the Series E round, which values the decision intelligence provider at $1.8bn.
"After closing our Series D investment round, Quantexa has been on a transformational journey, accelerating the growth of our global software business and firmly establishing our leadership position in the emerging Decision Intelligence category. In a challenging market we have doubled our ARR, our user base, and continue to penetrate new markets and industries. This infusion of capital will fuel further innovation, diversification, and expansion, and opens exciting options for our future."